PR Newswire
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
📈
AI Sentiment
Highly Positive
9/10
- Home
- CTXR
as of 02-17-2026 9:38am EST
$0.72
$0.04
-5.80%
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CRANFORD |
| Market Cap: | 20.1M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 491.0K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $2.97 | Next Earning Date: | 02-13-2026 |
| Revenue: | $3,944,111 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 147.57% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -34835708.0 | FCF Growth: | N/A |
AI-Powered CTXR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 15 hours ago
AI Recommendation
hold
Model Accuracy: 72.84%
72.84%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Citius Pharmaceuticals Inc. News
CTXR Breaking Stock News: Dive into CTXR Ticker-Specific Updates for Smart Investing
PR Newswire
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
📈
AI Sentiment
Highly Positive
8/10
Pharmaceutical Technology
Citius Oncology and Uniphar sign European distribution deal for Lymphir
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
📈
AI Sentiment
Highly Positive
9/10
Compare CTXR vs Leading Stocks
See how CTXR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CTXR Citius Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.